Medical Research Technology Offers

Yissum - Research Development Company of the Hebrew University posted this:

Naturally Occurring Compounds for Treating Pathogenic Factors Common to Cystic Fibrosis Cannabis project Derivatives of cannabinoids have an antimicrobial and anti biofilm effect on pseudomonas and candida which are major ethological pathogenic factors in CF Project ID : 6-2019-6720

Ukrainian Laboratories posted this:

Computer aided drug discovery services Otava Research Institute helps researchers around the world develop advanced solutions for the variety of research projects maximizing their efficiencies, and, most of all, respecting their budgets. Our experts are involved in the development of leading compounds at any stage of the R&D process: starting from target identification to lead optimization

Consejo Superior de Investigaciones Científicas posted this:

Transphagocytic T cells as anti cancer immunotherapy Transphagocytic T cells as anti cancer immunotherapy CSIC´s research group, in collaboration with scientists from the Centre of Molecular Biology “Severo Ochoa” (CBMSO-CSIC), the Autónoma University of Madrid and the Health Research Institute of the “La Princesa” University Hospital, developed a new method for anti-cancer immunotherapy based on transphagocytic lymphocytes (tiCD4+ T cells) Companies interested in a patent license or investors for creation of a start-up are being sought. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Overcoming resistance to Beta-lactam antibiotics in Bacterial species CSIC and the University of Würzburg have developed a new method to eliminate antibiotic-resistant bacterial infections using classical antibiotics previously discarded due the occurrence of antibiotic resistance. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

New treatment for epidermolysis bullosa and fibrosis CSIC, Carlos III University of Madrid and CIEMAT have repositioned drugs that stimulate endogline expression and modulate the TGF-β route for a new clinical use in the treatment of fibrosis, such as epidermolysis bullosa (EB). EB includes a heterogeneous group of rare hereditary diseases of the skin in which in its infantile incidence the patients are known as "butterfly children". It is a new therapy for a rare pathology, with potential in a wide spectrum of fibrosis, which would improve the possibilities of treatment of patients, improving their quality of life. Industrial partners from the pharmaceutical industry are being sought for its development in a wide variety of fibrotic pathologies through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Kits for cell culture based on hydrogel coatings CSIC and Complutense University of Madrid have developed new kits for cell culture based on cytocompatible hydrogels coated onto stiff substrates. Due to the excellent adhesion of the hydrogel to these substrates is possible to have mechanically robust platforms, easy to handle as required in a cellular biology laboratory. These new kits have been successfully tested showing an excellent cellular proliferation on the surface of the hydrogel. Besides, this technology allows the detachment of a cell monolayer without the need of chemical or biological agents preserving the viability of cell harvesting. Industrial partners from the biotechnology with expertise in cell culture are being sought to collaborate through a patent license agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Biotechnological production of 11α hydroxylated steroids using recombinant bacteria.CSIC has developed a procedure for the biotechnological production of 11α hydroxylated steroids by generating and subsequent use of recombinant bacteria. These recombinant bacteria allow to perform microbial biotransformation processes that result in 11αhydroxylated steroid compounds from raw materials such as phytosterols and intermediate products efficiently and economically. These compounds have numerous applications in pharmacology. Companies are sought for implementing and commercializing the new technology under patent license agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Compounds for the treatment of optic neuritis CSIC and the University of Athens have found that secoiridoids, such as oleacein and oleocanthal, are useful to prevent or treat neuropathies that conduct to optic nerve injury, such as optic neuritis. A company dealing with pharmaceutical or nutraceutical compositions for ophtalmic applications is sought for licensing agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Peptide for cancer control linked to IL13R R R α α 2 2 o o v v e e r r e e x x p p r r e e s s s s i i o o n n CSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Piperidine derivatives for the control of Parkinson's and Alzheimer's CSIC has synthesized a series of piperidine derivatives that are capable of inhibiting the activity of the enzyme phosphodiesterase-8 (PDE8). This inhibitory activity makes them useful for the treatment of neurodegenerative diseases in which this enzyme is overexpressed. The compounds developed are, therefore, a new therapeutic alternative for Alzheimer's disease, and Parkinson, among others. Industrial partners from pharmaceutical industry are being sought to develop and commercialized the compounds through a patent licence agreement. An offer for Patent Licensing

Consejo Superior de Investigaciones Científicas posted this:

Regulatory compounds of synaptic transmission for the treatment of neurological diseases The CSIC and IRYCIS (Ramón y Cajal Institute for Health Research) have developed a group of compounds. These compounds have the ability to regulate the number of synapses that are formed between neurons, as well as the probability that neurotransmitters are released from these, because they have the capability of modulate the interactions that take place between the regulatory proteins NCS-1 and Ric8a that regulate these two independent processes. Due to these neuromodulatory properties, these compounds are useful for the treatment of neurological diseases as Alzheimer's disease, Huntington or Parkinson's diseases among others. Industrial partners from the ophthalmic or pharmaceutical industry are being sought to collaborate through a patent license agreement. An offer for Patent Licensing

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

New compound to successfully treat degenerative diseases of the retina The research group "Neurobiología del sistema visual y terapia de enfermedades neurodegenerativas" of the University of Alicante has discovered the use of the compound 3-(2-isothiocyanatethyl)-5-methoxy-1H-indol, and its pharmaceutically acceptable salts, for the preventive or therapeutic treatment of degenerative diseases of the retina, such as: pigmentary retinosis, diabetic retinopathy, glaucoma or age-related macular degeneration. This compound has demonstrated, in vitro and in vivo, its neuroprotective capacity in various models under laboratory conditions. This compound is characterized by a 20% increase in neuronal survival, a 35% increase in visual acuity, and a 15% increase in contrast sensitivity. Therefore, it has very promising properties that could position it as the first effective treatment against degenerative diseases of the retina. We are looking for companies interested in acquiring this patent for commercial exploitation.

IDIBELL posted this:

Diagnostic test for azoospermia origin ✓ Non-invasive azoospermia biomarkers & Kit development ✓ High sensitivity and specificity (>90%) ✓ Effective azoospermia test in seminal plasma to avoid unnecessary biopsies.

IDIBELL posted this:

Exosomal miRNAs in seminal plasma as non-invasive markers of prostate cancer diagnosis Identified miRNAs, from the semen samples, could be used as non-invasive biomarkers that contribute in the diagnosis/prognosis of malignant prostate cancer.

Nadiia Kachaput posted this:
Innovation Manager at Ukrainian Laboratories

Synthesis of dual-targeted inhibitors of HDAC1 and mTOR for cancer therapy Our offer is a chemical optimization service - synthesis of two-target specific set of pyrazolo[3,4-d]pyrimidine derivatives as dual-targeted inhibitors of HDAC1 and mTOR. We will synthesize these novel analogs only upon your request.

Medical Research Technology Offers

Innovation Resources

Sitemaps

Support

Company

Top Posts Categories

Recognitions

Medical Research Technology Offers

Recognitions

Follow us